Biotech Values

[poorgradstudent]

Re: CNAT

Is the biology really so black and white? Surely, there are many instances in which intervening in a given pathway can have both positive and negative consequences.

No doubt that there are contextual situations, so I agree with you there. But it strikes me that those are often the cases where we'll see a company targeting an isoform or variant of the target of interest. For example, PDE5 versus pan-PDE inhibition, CDK4/6 rather than pan-CDK or JAK1/2 rather than pan-JAK inhibition.

I just found it surprising that they would want to push a pan-caspase inhibitor rather than focusing on a subset.